The short answer. For GHK-Cu, the route decides the answer. As of September 25, 2026, non-injectable GHK-Cu is being returned to FDA’s 503A Category 1, so a pharmacy may compound topical preparations under FDA’s interim policy. Injectable GHK-Cu has no pathway, and FDA has flagged an immunogenicity risk.
| FDA approved | No. |
|---|---|
| 503A, topical and other non-injectable | Returning to Category 1 after a May 5, 2026 clarification. FDA plans to consult its advisory committee before the end of February 2027. |
| 503A, injectable | No pathway. Listed by FDA as nominated then withdrawn, with an immunogenicity concern. |
| 503B outsourcing facility | No pathway. |
| Cosmetic | A topical product can be a cosmetic, a drug or both, depending on its claims. |
| MDside position | Topical only. We do not order injectable GHK-Cu. |
| Last verified | 2026-09-25 |
What happened in April and May 2026
GHK-Cu had been in 503A Category 1. On April 22, 2026 FDA removed it after a nominator withdrew. On May 5, 2026 the nominator clarified that it had withdrawn only the injectable route. FDA’s May 14, 2026 update states that non-injectable GHK-Cu is being added back to Category 1 and that FDA intends to consult its advisory committee before the end of February 2027.
Injectable GHK-Cu carries a named risk
FDA’s safety-risk page lists injectable GHK-Cu under substances nominated and then withdrawn. FDA’s stated concern is that compounded injectable GHK-Cu may pose a risk of immunogenicity because of aggregation and peptide-related impurities, with limited human data.
Topical is where the cosmetic question comes in
A topical copper peptide product sold for appearance can be a cosmetic. The same product becomes a drug once its claims describe treating a condition or changing the structure or function of the body. Claims, labels and your website decide which. Keep topical GHK-Cu marketing to appearance language.
What this means for you
Keep GHK-Cu to topical use, sourced either as a cosmetic product or as a 503A compounded preparation for a named patient. Remove injectable GHK-Cu. Audit your website for claims about healing or tissue repair, which turn a cosmetic into a drug. Our aesthetics program runs on that line.
Read next
Frequently asked questions
Is GHK-Cu legal?
It depends on the route. As of September 25, 2026, non-injectable GHK-Cu is returning to FDA’s 503A Category 1, so a pharmacy may compound topical preparations for a named patient. Topical cosmetic products are lawful with appearance-only claims. Injectable GHK-Cu has no compounding pathway.
Can GHK-Cu be injected?
Not through any lawful compounding pathway. The injectable route was withdrawn from nomination in 2026, and FDA lists injectable GHK-Cu among substances that may present significant safety risks, citing immunogenicity from aggregation and impurities and limited human data. Topical use is the only route with a pathway.
Is a GHK-Cu serum a cosmetic or a drug?
It depends on the claims. A serum sold to improve appearance can be a cosmetic. Claims about healing, repairing tissue or treating a condition make it a drug under the Federal Food, Drug, and Cosmetic Act, which brings approval requirements with it.
Primary sources. Last verified September 25, 2026. Corrections are welcome: contact us.
- FDA, 503A bulk drug substance categories (updated May 14, 2026)
- FDA, Certain bulk drug substances that may present significant safety risks (updated Apr 22, 2026)
- FDA, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A (Jan 2025)
- FDA, 503B bulk drug substance categories (updated Mar 21, 2025)
- FDA, Is it a cosmetic, a drug, or both?
- FDA warning letter, Tailor Made Compounding (Apr 1, 2020)
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.